Alzheimer

A large study of nearly 2 million older adults has found that cerebral amyloid angiopathy, a condition where amyloid proteins build up in brain blood vessels, sharply increases the risk of dementia. Within five years of diagnosis, people with this disorder were four times more likely to develop dementia than those without it, even absent a history of stroke. The findings, drawn from Medicare records, underscore the need for early cognitive screening in affected individuals.

26 gennaio 2026 Riportato dall'IA

Researchers have uncovered how amyloid beta and inflammation may both trigger synapse pruning in Alzheimer's disease through a common receptor, potentially offering new treatment avenues. The findings challenge the notion that neurons are passive in this process, showing they actively erase their own connections. Led by Stanford's Carla Shatz, the study suggests targeting this receptor could preserve memory more effectively than current amyloid-focused drugs.

Gli scienziati europei hanno sviluppato un metodo preliminare per identificare l'Alzheimer utilizzando una goccia di sangue essiccato da un dito, raggiungendo l'86% di accuratezza nel rilevare la patologia amiloide. Lo studio, validato su 337 pazienti di diversi paesi, è pubblicato su Nature Medicine e mira a semplificare la diagnosi precoce di questa malattia che colpisce oltre 50 milioni di persone in tutto il mondo.

03 gennaio 2026 Riportato dall'IA Verificato

Researchers from Nanyang Technological University, Singapore report that “enlarged perivascular spaces” — small fluid-filled channels around brain blood vessels that can be seen on routine MRI — were more common in people with mild cognitive impairment and were associated with several blood-based Alzheimer’s disease biomarkers in a multi-ethnic Singapore cohort of 979 participants.

Alzheimer's trials are shifting to a multi-target approach inspired by cancer research, even after failures with Novo Nordisk's semaglutide. Only two drugs, Eli Lilly's Kisunla and Eisai and Biogen's Leqembi, are widely approved to slow progression. This evolution treats the brain-wasting disease as a complex system, seeking new ways to halt it amid its global impact.

05 dicembre 2025 Riportato dall'IA

Eric Topol, author of 'Super Agers,' envisions AI analyzing retinal scans to detect Alzheimer's disease. In a recent interview, he highlights how such technology could transform medical diagnostics. The discussion emphasizes proactive health monitoring starting in one's forties.